Robert Wenham is Chair, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 324 publications with 8,540 citations (h-index 45); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Robert Wenham, MD, is Chair, Moffitt Cancer Center. The public record shows 324 publications with 8,540 citations (h-index 45), centered on Ovarian cancer diagnosis and treatment, BRCA gene mutations in cancer, PARP inhibition in cancer therapy. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 12 companies.
- Most recent indexed publication: 2023 · Journal of clinical oncology
- Top research focus: Ovarian cancer diagnosis and treatment
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 110.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- PTX-200 and Carboplatin in Ovarian Cancer
Sponsor: Prescient Therapeutics, Ltd.
Industry payments
Updated 24 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year20257 payments
- On Target Laboratories, IncProgram year20252 payments
- Genmab U.S., Inc.Program year20252 payments
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Poly(ADP-Ribose) Polymerase Inhibitor100%Rubraca100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 24 Oct 2026
50 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
Journal of clinical oncology
Clinical Trial2023 - Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Journal of clinical oncology
Clinical Trial2022 - Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors.
Molecular cancer therapeutics
Article2022
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04Monsel's Solution: A Brief HistoryArticle379 citations2002
- 05
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/robert-wenham-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
moffitt.org/research-science/researchers/robert-wenham
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗ - Other
aacr.org/governance/robert-m-wenham-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Awards & honors
honors on the public record- Molly Cade Ovarian Cancer Research Award
Gynecologic Cancer Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Media & interviews
press, podcasts and appearances- Ask the Expert: Ovarian Cancer
interview with Dr Robert Wenham (podcast)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →liveforeverish.podbean.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ijgcgroup.podbean.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Nikhil Khushalani, MD
Moffitt Cancer Center
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute